Dr. Marcus Messmer
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 148
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Johns Hopkins University School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD474051 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Temple University Hospital Philadelphia, PA
Medical groups
- Temple Faculty Practice Plan Inc (1,368 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 148
- Services billed
- 355
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 182 | 94 |
| Established patient office or other outpatient visit, 40-54 minutes | 99 | 50 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 94 |
| Prednisone Other prescribers in Philadelphia, PA | 40 |
| Calquence (acalabrutinib maleate) | 33 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 32 |
| Allopurinol Other prescribers in Philadelphia, PA | 30 |
| Olanzapine Other prescribers in Philadelphia, PA | 29 |
| Acyclovir Other prescribers in Philadelphia, PA | 26 |
| Tazverik (tazemetostat hydrobromide) | 17 |
| Venclexta (venetoclax) | 16 |
| Mirtazapine Other prescribers in Philadelphia, PA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 41 payments worth $18,900 in total to this clinician.
| Incyte Corporation | $15,350 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,981 |
| Beone Medicines USA, Inc. | $149 |
| Daiichi Sankyo Inc. | $142 |
| Genentech USA, Inc. | $102 |
| Pharmacosmos Therapeutics Inc. | $38.55 |
| Adc Therapeutics America, Inc. | $36.66 |
| Regeneron Pharmaceuticals, Inc. | $28.97 |
| Compensation for services other than consulting (speaking, faculty) | $10,725 |
|---|---|
| Consulting Fee | $6,170 |
| Food and Beverage | $1,055 |
| Travel and Lodging | $950 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $3,300 |
| Incyte Corporation Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $3,300 |
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Incyte Corporation Sep 18, 2025 | Consulting Fee Monjuvi · Oncology | $1,650 |
| Incyte Corporation Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,375 |
| Incyte Corporation Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $825 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Incyte Corporation Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| Incyte Corporation Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $3,300 |
| Incyte Corporation Nov 19, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Lancaster, PA | $87.78 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
| Incyte Corporation Oct 9, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
| Incyte Corporation Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $3,300 |
| Incyte Corporation Oct 1, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Reading, PA | $67.20 |
| Incyte Corporation Sep 18, 2025 | Consulting Fee Monjuvi · Oncology | $1,650 |
| Incyte Corporation Sep 5, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Houston, TX | $400 |
| Incyte Corporation Sep 5, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Houston, TX | $96.74 |
| Incyte Corporation Sep 5, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Houston, TX | $39.82 |
| Incyte Corporation Sep 4, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Houston, TX | $259 |
| Incyte Corporation Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $825 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,375 |
| Incyte Corporation Jul 31, 2025 | Consulting Fee Monjuvi · Oncology | $550 |
| Incyte Corporation May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $275 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $902,377 in research payments for these studies, mostly to the institutions running them.
- Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Beone Medicines Ltd. · Recruiting · NCT06634589 - Pilot study: Unleashing BCL2 inhibition in follicular lymphoma with zanubrutinib
Beigene USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.